Author of

• 16831

  +

  P1.06 - Poster Session with Presenters Present (ID 458)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16869

    +

    P1.06-038 - Survival and Prognostic Factors of Oligometastatic Non-Small Cell Lung Carcinoma: A Single Center Experience (ID 5283)

    14:30 - 14:30  |  Author(s): E. Tunç
    • Abstract

    Background:
    In patients without targeted mutations platinum-based chemotherapy is still current treatment method with a median survival rates of 8-11 months. Patients with single side oligo-metastatic disease should be consider for curative aggressive therapies for both primary and metastatic sides for better survival (NCCN 2016).
    
    Methods:
    Totally 19 oligo-metastatic NSCLC patients was evaluated retrospectively by using hospital database. All patients had single metastatic side.
    
    Results:
    Among 19 eligible patents there was male predominance (n= 16, 84.2%). Eight patients had co-morbidities requiring regular medication. Histopathological, there were 13 (68.4%) adenocarcinoma and 6 (31.6%) non-adenocarcinoma. While brain was the most common site for metastasis 10 (52.6%), it was followed by bone (n=6, 31.6%). Treatments for primary tumour side were surgery (n=6, 31.7%), concurrent CRT (n=5, 26.3%) and sequential CRT (n=1, 5.3%). Median follow-up for whole cases were 59.1 weeks. Median overall survival (OS) and progression free survival (PFS) were 140 (±33.7) and 76 (±24.2) weeks respectively. Progressions were observed mostly in 45.4. week. Univariate cox regression analyses for OS and PFS is indicated in Table 1. Clinical T and N staging had significant relation with OS (p=0.02 and 0.03 respectively). There was no relation between bone or brain metastasis and histopathology, gender, clinical T and N staging. Median survival after first progression (SAFP) was 63 weeks (±SS 29.05). Among study parameters only clinical T staging had significant relation with SAFP (p=0.026). Median SFAP was better in patients with progression of primary tumour however median OS was better in patients with progression of distant metastasis (p>0.05).

    Factor	OS	PFS
    	Hazard Ratio	p	Hazard Ratio	p
    Age (cut-off=65)	1.034 (0.18-5.1)	0.96	0.4 (0.1-2.2)	0.3
    Co-morbidity	2.3 (0.54-9.8)	0.24	3.4 (0.8-14)	0.07
    Brain Metastasis	0.88 (0.21-3.6)	0.86	1.5 (0.42-5.45)	0.52
    Histopathology (adeno vs non-adeno)	0.22 (0.03-1.4)	0.10	0.67 (0.16-2.8)	0.6
    Bone Metastasis	1.78 (0.43-7.31)	0.42	1.7 (0.47-6.6)	0.4
    pN Staging (n0 and N1-2)	0.12 (0-173)	0.21	0.94 (0.22-4.02)	0.94
    cT Staging	2.17 (1-4.7)	0.02	1.11 (0.73-1.81)	0.54
    cN Staging (n0 and N1-2)	2.3 (0.86-6.6)	0.03	1.77 (0.79-3.97)	0.1
    Non-surgical curative treatment	1.88 (0.41-8.52)	0.42	1.9 (0.50-7.38)	0.34
    Surgery	0.31 (0.06-1.65)	0.14	0.21 (0.02-1.78)	0.09

    
    
    Conclusion:
    Even oligo-metastatic NSCLC means stage 4 of disease, curative treatment approaches for both primary and metastasis sides can increase patients’ prognosis than other stage 4 cases. Similar to the existed retrospective studies we had OS more than 2 years and PFS more than 1 year.